CIA Cornerstone Industries International Inc. (Tier2)

ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today reported on its
business highlights and financial results for the year ended December 31, 2007. 
Additionally, ProMetic announces that its 2007 Annual Report has been filed on
Sedar (www.sedar.com) and is now available on its web site at www.prometic.com.


"The year 2007 has seen the expansion of ProMetic's Protein Technologies
business resulting in an escalating revenue growth that is projected to make
this unit EBITDA positive in 2008," stated Mr. Pierre Laurin, President and
Chief Executive Officer of ProMetic.  "Following on PBI-1402's positive clinical
results ProMetic will continue to concentrate its resources to advance its
partnering discussions."


Highlights

Therapeutics

- PBI-1402 positive Phase II clinical results in patients with chemotherapy
induced anemia ("CIA") presented at the Annual Meeting of the American Society
of Hematology;


- PBI-1402 positive pre-clinical data in anemia related to renal failure,
demonstrating efficacy of PBI-1402 oral treatment with minimal endogenous
erythropoietin - setting the stage for Phase II chronic kidney disease ("CKD")
pre-dialysis clinical trial;


- Analogues to PBI-1402 and New Chemical Entities ("NCEs") have been discovered
with confirmed in vivo activity on anemia.


Protein Technologies

- 2007 revenue increased to $8.4M in addition to $1.6M of deferred revenues as
of December 31, 2007;


- UK and Ireland National Blood Services initiate pre-adoption trials for
P-Capt(R) prion capture filter for blood units;


- Prion capture filter scaled-up for industrial use by a leading European plasma
fractionation company;


- Strategic alliance and licensing agreements for plasma-derived therapeutics with:

-- Kedrion for Hyperimmune products - first product Hepatitis B hyperimmune
value to ProMetic could exceed $30 M annually;


-- Wuhan Institute of Biological Products for China and Blue Blood for Taiwan -
South East Asia - representing potential annual revenue of $60M  when plasma
fractionation companies are fully operational;


- Strategic alliance with Sartorius and the launch of ProMetic's Development and
Technology Transfer Center in Maryland for protein-based therapeutics -
instrumental in securing the licensing agreements;


- Continued growth in sales of core products in the Affinity Ligand adsorbent
range, with successful scale-up by a large bio-manufacturing client to 800L
column;


- Initiation of the development phase that will allow the Instituto de
Tecnologia do Parana ("Tecpar") to manufacture complex biopharmaceutical
products for the Brazilian and South American markets;


- Key performance milestones achieved for ProMetic's new MAbsorbent(TM) ligands
targeting the purification of MAbs and Fabs through validation in collaboration
with seven leading antibody producer companies in the United States and Europe.


2008 Milestones

Therapeutics

- Additional PBI-1402 Phase II clinical results from chemotherapy-induced anemia
("CIA") trials;


- Initiation of the PBI-1402 Phase II chronic kidney disease ("CKD")
pre-dialysis clinical trial;


- Emphasis on accelerated partnering activities surrounding PBI-1402.

Protein Technologies

- Protein Technologies business expected to be EBITDA positive;

- Additional licensing and / or technology transfer agreements for plasma proteins;

- Further licencing and partnering agreements for the Mimetic Ligand(TM) technology;

- Adoption of the P-Capt(R) prion filter in Europe.

2007 Financial Results

Year ended December 31, 2007

The following information should be read in conjunction with the audited
financial statements for the year ended December 31, 2007 as well as the annual
Management Discussion and Analysis for the year ended December 31, 2007
including results of the fourth quarter.


Total revenues for 2007, which were derived from the protein technology unit,
were $8.4 million compared with $2.6 million in 2006. In addition, as at
December 31, 2007, deferred revenues were at $1.6 million.


Research and development expenses and costs of goods sold increased to $19.1
million for the year ended December 31, 2007 from $15.3 million for the same
period in 2006.


Administrative and marketing expenses decreased significantly to $6.6 million
for the year ended December 31, 2007 from $7.6 million for the year ended
December 31, 2006.


The Company incurred a net loss of $22.3 million for the year ended December 31,
2007 as compared to a net loss of $30.5 million, for the same period last year.


Cash and cash equivalent as at December 31, 2007 was $2.2 million compared to
$20.8 million in 2006 when the Company closed a financing in December 2006. 
During the first quarter of 2008, the Company collected more than $4.5 million
between licensing agreements, sales to customers, R&D tax credit loan and small
private placements.


About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical company
specialized in the research, development, manufacture and marketing of a variety
of commercial applications derived from its proprietary Mimetic Ligand(TM)
technology. This technology is used in large-scale purification of biologics and
the elimination of pathogens. ProMetic is also active in therapeutic drug
development with the mission to bring to market effective, innovative, lower
cost, less toxic products for the treatment of hematology and cancer. Its drug
discovery platform is focused on replacing complex, expensive proteins with
synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada),
ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing
facilities in the U.K. and business development activities in the U.S., Europe,
Asia and in the Middle-East.


Forward Looking Statements

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations on page 21 of ProMetic's Annual Information Form for the year ended
December 31, 2007, under the heading "Risk Factors".  As a result, we cannot
guarantee that any forward-looking statement will materialize. We assume no
obligation to update any forward-looking statement even if new information
becomes available, as a result of future events or for any other reason, unless
required by applicable securities laws and regulations.

Cornerstone Industries International Inc. (Tier2) (TSXV:CIA)
Historical Stock Chart
From Jun 2024 to Jul 2024

Cornerstone Industries International Inc. (Tier2) (TSXV:CIA)
Historical Stock Chart
From Jul 2023 to Jul 2024